SG's AUM Biosciences to list in US via SPAC merger

Singapore-based clinical-stage biotechnology company AUM Biosciences plans to go public in the US through a merger with Mountain Crest Acquisition Corp V, a publicly-traded special purpose acquisition company, in a transaction that reflects a pre-money equity value of $400 million for AUM, according to a statement.